Prothena Corporation PLC
PRTA
ISIN IE00B91XRN20 / Valor 20224443
Prothena Corporation PLC
UMushroom community rating:
About company
Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (13.10.2025):
Prothena Corporation PLC reported its financial results for the second quarter and the first six months of 2025, highlighting significant developments in its neurodegenerative diseases portfolio and anticipating future milestones. The company continues to invest in its research and development pipeline while managing its cash position effectively.
Net Loss
For the second quarter of 2025, Prothena reported a net loss of $125.8 million, and a net loss of $186.0 million for the first six months of 2025. These losses include restructuring charges and non-cash income tax expenses, compared to a net income of $66.9 million for Q2 2024 and a net loss of $5.4 million for the first half of 2024.
Revenue
Total revenue was $4.4 million for the second quarter and $7.2 million for the first six months of 2025, primarily from collaboration revenue with Bristol Myers Squibb. This marks a significant decrease from $132.0 million and $132.1 million for the same periods in 2024.
Research and Development Expenses
R&D expenses amounted to $40.5 million for Q2 and $91.3 million for the first half of 2025, down from $57.5 million and $121.6 million in the previous year. The reduction was driven by lower clinical trial, manufacturing, and personnel expenses.
General and Administrative Expenses
G&A expenses were $15.9 million for the second quarter and $33.5 million for the first six months of 2025, slightly decreased from $16.1 million and $33.6 million in 2024. This decrease is attributed to lower share-based compensation expenses.
Cash Position
As of the quarter-end, Prothena maintained a cash and restricted cash position of $372.3 million. Net cash used in operating and investing activities was $46.4 million for the second quarter and $99.8 million for the first six months of 2025.
Future Initiatives
Prothena plans to convene an Extraordinary General Meeting by year-end 2025 to propose a reduction of share capital for a potential share redemption program. Additionally, the company anticipates significant clinical milestones and potential revenue from collaboration agreements in the coming years.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
564 M
Market cap (USD)
461,186
Daily traded volume (Shares)
15.25 / 14.66
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Daniel Bruggmann
Daniel Bruggmann
Daniel Bruggmann
EQUITIES OF THE SAME SECTOR
